Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 59
2021 79
2022 23
2023 11
2024 10
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Exploring the long-term hydroxychloroquine's effects on COVID-19 outcomes in patients with autoimmune diseases: a systematic review and meta-analysis.
Amal HM, Mohamed AMG, Abdel-Halim MO, Hassan MS, Khorshid OA, Osman WA. Amal HM, et al. Eur J Clin Pharmacol. 2026 May 7;82(6):140. doi: 10.1007/s00228-026-04066-y. Eur J Clin Pharmacol. 2026. PMID: 42091717
Eligible studies involved 229,142 autoimmune patients treated with HCQ, of which 197,118 patients were diagnosed with COVID-19. In 14 observational studies (196,965 patients), HCQ use was associated with a lower overall mortality rate by 21% in patients with autoimm …
Eligible studies involved 229,142 autoimmune patients treated with HCQ, of which 197,118 patients were diagnosed with COVID-19 …
Incorporating preprints in systematic reviews: a preliminary study of a novel method for rapid evidence synthesis.
Tong J, Sun Y, Hubbard RA, Saine ME, Xu H, Zuo X, Lin L, Weng C, Schmid CH, Kimmel SE, Umscheid CA, Cuker A, Chen Y. Tong J, et al. J Am Med Inform Assoc. 2025 Nov 1;32(11):1654-1663. doi: 10.1093/jamia/ocaf111. J Am Med Inform Assoc. 2025. PMID: 40901701
OBJECTIVES: By October 1, 2024, over 450,000 COVID-19 manuscripts were published, with 10% posted as unreviewed preprints. While they accelerate knowledge sharing, their inconsistent quality complicates systematic studies. ...RESULTS: This preliminary study employed …
OBJECTIVES: By October 1, 2024, over 450,000 COVID-19 manuscripts were published, with 10% posted as unreviewed preprints. Whi …
Hydroxychloroquine use during the first COVID-19 wave: a case study highlighting the urgent need to enhance research practices within the publication ecosystem.
Beaudart C, Musuamba F, Locquet M, Dogné JM, Douxfils J. Beaudart C, et al. Arch Public Health. 2025 Apr 27;83(1):115. doi: 10.1186/s13690-025-01596-2. Arch Public Health. 2025. PMID: 40289186 Free PMC article.
However, the reliability of such data is crucial, as evidenced by significant cases like the retracted study on hydroxychloroquine (HCQ) during the COVID-19 pandemic. This paper examines the retraction of a widely publicized study by Pradelle et al., which co …
However, the reliability of such data is crucial, as evidenced by significant cases like the retracted study on hydroxychloroquine (H …
Risk factors of COVID-19 related hospitalization of paediatric patients with rheumatic diseases: a systematic review and meta-analysis.
Zhao Q, Wallace B, Ronis T, Jung L. Zhao Q, et al. Rheumatology (Oxford). 2025 May 1;64(5):2369-2376. doi: 10.1093/rheumatology/keae664. Rheumatology (Oxford). 2025. PMID: 39657248 Free article.
Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. We aimed to examine the risk factors for COVID-19-related hospitalization in paediatric patients with RDs. ...RESULTS: Eight …
Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. …
The efficacy and safety of hydroxychloroquine at different doses and courses for COVID-19 prevention: a systematic review and network meta-analysis.
Wang H, Yang Q, Mao Y, Ding H, Huang P, Zhan Z. Wang H, et al. Expert Rev Anti Infect Ther. 2024 Dec;22(12):1209-1220. doi: 10.1080/14787210.2024.2413419. Epub 2024 Oct 9. Expert Rev Anti Infect Ther. 2024. PMID: 39365687
BACKGROUND: The optimal strategy for using hydroxychloroquine to prevent coronavirus disease 2019 (COVID-19) in patients, either before or after exposure, remains unclear. ...RESULTS: A total of 20 RCTs involving 12,372 patients were included. Meta- …
BACKGROUND: The optimal strategy for using hydroxychloroquine to prevent coronavirus disease 2019 (COVID-19) in patient …
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK, Mukaka M, Callery JJ, Llewelyn MJ, Cruz CV, Dhorda M, Ngernseng T, Waithira N, Ekkapongpisit M, Watson JA, Chandna A, Nelwan EJ, Hamers RL, Etyang A, Beg MA, Sow S, Yavo W, Allabi AC, Basnyat B, Sharma SK, Amofa-Sekyi M, Yonga P, Adler A, Yuentrakul P, Cope T, Thaipadungpanit J, Rienpradub P, Imwong M, Abdad MY, Blacksell SD, Tarning J, Goudjo FF, Dossou AD, Konaté-Touré A, Assi SB, Ouffoué K, Nasronudin N, Rachman BE, Romadhon PZ, Dewanto DD, Heryana MO, Novi T, Pasaribu AP, Mutiara M, Nasution MPR, Khairunnisa K, Dalimunthe FA, Airlangga E, Fahrezzy A, Subronto Y, Ananda NR, Rahardjani M, Rimainar A, Lucinde RK, Timbwa M, Onyango OE, Agutu C, Akech S, Hamaluba M, Kipyego J, Ngachi O, Haidara FC, Traoré OY, Diarra F, Khanal B, Dahal P, Shrestha S, Rijal S, Kabore Y, Adehossi E, Guindo O, Qamar FN, Kazi AM, Woodrow CJ, Laird S, Cheeba M, Ayles H, Cheah PY, Taylor WRJ, Batty EM, Chotivanich K, Pukrittayakamee S, Phumratanaprapin W, von Seidlein L, Dondorp A, Day NPJ, White NJ; COPCOV Collaborative Group. Schilling WHK, et al. PLoS Med. 2024 Sep 12;21(9):e1004428. doi: 10.1371/journal.pmed.1004428. eCollection 2024 Sep. PLoS Med. 2024. PMID: 39264960 Free PMC article. Clinical Trial.
Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. ...The primary endpoint was symptomat …
Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, al …
The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis and clinical assessment: an updated meta-analysis of randomized trials.
Han X, Shi W, Yang Y. Han X, et al. J Thorac Dis. 2024 May 31;16(5):2983-2993. doi: 10.21037/jtd-23-1043. Epub 2024 May 29. J Thorac Dis. 2024. PMID: 38883686 Free PMC article.
The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) were the most frequently cited as potential treatments and preventatives against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ...Randomized controlled trials (RCTs) …
The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) were the most frequently cited as potential treatments and preventativ …
Comprehensive analysis of gastrointestinal side effects in COVID-19 patients undergoing combined pharmacological treatment with azithromycin and hydroxychloroquine: a systematic review and network meta-analysis.
Pacheco G, Lopes ALF, Oliveira AP, Corrêa WRM, Lima LDB, Souza MHLP, Teles AS, Nicolau LAD, Medeiros JVR. Pacheco G, et al. Crit Rev Toxicol. 2024 Jul;54(6):345-358. doi: 10.1080/10408444.2024.2348169. Epub 2024 Jun 11. Crit Rev Toxicol. 2024. PMID: 38860720
During the COVID-19 pandemic, several drugs were repositioned and combined to quickly find a way to mitigate the effects of the infection. ...The symptoms of vomiting and nausea were evaluated through a network meta-analysis, while the symptom of abdom …
During the COVID-19 pandemic, several drugs were repositioned and combined to quickly find a way to mitigate the effects of th …
Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis.
Kamal M, Baudo M, Joseph J, Geng Y, Mohamed O, Rahouma M, Greenbaum U. Kamal M, et al. Healthcare (Basel). 2024 Feb 23;12(5):530. doi: 10.3390/healthcare12050530. Healthcare (Basel). 2024. PMID: 38470640 Free PMC article. Review.
This systematic review and meta-analysis aims to identify the outcomes of stem cell transplant (SCT) patients during the COVID-19 era. ...In total, 36 eligible studies were included out of 290. The PER of COVID-19-related deaths and CO …
This systematic review and meta-analysis aims to identify the outcomes of stem cell transplant (SCT) patients during the CO …
Effect of Hydroxychloroquine and Azithromycin Combination Use in COVID-19 Patients - An Umbrella Review.
Nag K, Tripura K, Datta A, Karmakar N, Singh M, Singh M, Singal K, Pradhan P. Nag K, et al. Indian J Community Med. 2024 Jan-Feb;49(1):22-27. doi: 10.4103/ijcm.ijcm_983_22. Epub 2024 Jan 12. Indian J Community Med. 2024. PMID: 38425958 Free PMC article. Review.
BACKGROUND: Hydroxychloroquine and Azithromycin combination was used rampantly in management of COVID-19 patients in different countries. ...MATERIAL AND METHODS: We included all the systematic review with or without meta-analysis reporting the …
BACKGROUND: Hydroxychloroquine and Azithromycin combination was used rampantly in management of COVID-19 patients in di …
164 results